Beta
Caffeine (pharmacokinetic)
supplement Under reviewCaffeine is a naturally occurring methylxanthine found in coffee, tea, cocoa, many soft drinks, and numerous over‑the‑counter and sports supplements. From a pharmacokinetic standpoint, it is rapidly and almost completely absorbed after oral ingestion, widely distributed throughout body water, readily crosses cell membranes including the blood–brain barrier, and undergoes extensive hepatic metabolism before being excreted in urine. In healthy adults, peak blood levels typically occur within about 30–60 minutes of ingestion, and only a small fraction of the dose is eliminated unchanged in urine. Caffeine is metabolized mainly in the liver by cytochrome P450 1A2 into active metabolites such as paraxanthine, theobromine, and theophylline, which themselves contribute to its physiological effects. Its elimination half‑life in healthy adults commonly falls in the range of roughly 3–7 hours, but can vary widely due to genetic differences in CYP1A2 activity, smoking status, liver function, pregnancy, hormonal contraceptives, and other environmental factors. At usual dietary and supplemental doses, caffeine generally exhibits linear pharmacokinetics, although saturable metabolism and dose‑dependent changes in clearance can appear at higher single doses. In everyday use, these pharmacokinetic properties help explain why caffeine produces relatively rapid-onset central nervous system stimulation, enhanced alertness, and improved physical performance, and why its effects can persist for several hours. They also underlie common issues such as sleep disruption when taken late in the day, inter‑individual differences in sensitivity, and clinically relevant interactions with drugs that share hepatic metabolic pathways or are affected by changes in gastric emptying or liver enzyme activity.
Research summary
Human pharmacokinetic research on caffeine is extensive, encompassing hundreds of studies in healthy volunteers across a broad range of doses and formulations. These studies consistently show rapid and complete oral absorption, peak plasma levels within about an hour, large inter‑individual variability in half‑life and clearance, and predominant hepatic metabolism via CYP1A2 to paraxanthine and other metabolites. Work using population pharmacokinetic modeling, crossover designs, and bioequivalence studies has established robust estimates of parameters such as clearance, volume of distribution, half‑life, and metabolite formation in healthy adults. The overall research consensus is that, in healthy humans, caffeine behaves largely as a low‑extraction, hepatically metabolized drug with mostly linear pharmacokinetics over typical intake ranges, but with clear dose‑dependence and saturable metabolism at higher single doses. Beverage matrix, temperature, and rate of consumption have only minor influence on exposure, while genetic polymorphisms, smoking, liver disease, pregnancy, and certain medications can markedly alter caffeine pharmacokinetics. These insights support current guidance on safe daily intake, help interpret individual variability in response and side‑effects, and inform clinical decisions about drug–caffeine and coffee–drug interactions.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Caffeine (pharmacokinetic) to your stack to report effects
Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models.
Nehlig A, Debry G, et al.
No reports yet
Be the first to report this effect and help the community.
Add Caffeine (pharmacokinetic) to your stack to report effects
Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models.
Nehlig A, Debry G, et al.
No reports yet
Be the first to report this effect and help the community.
Add Caffeine (pharmacokinetic) to your stack to report effects
Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults.
Lebofsky M, O'Neal E, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Caffeine (pharmacokinetic) to your stack to report effects
Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function.
Newton R, Broughton LJ, Lind MJ, Morrison PJ, et al.
No reports yet
Be the first to report this effect and help the community.
Add Caffeine (pharmacokinetic) to your stack to report effects
Caffeine and pharmacokinetics: plasma and salivary profiles and influence of abstinence on CYP1A2 metrics
Chen J, Marshman Z, et al.
Research (4 studies)
Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults.
Lebofsky M, O'Neal E, et al.
Caffeine and pharmacokinetics: plasma and salivary profiles and influence of abstinence on CYP1A2 metrics
Chen J, Marshman Z, et al.
Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models.
Nehlig A, Debry G, et al.
Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function.
Newton R, Broughton LJ, Lind MJ, Morrison PJ, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!